Loading clinical trials...
Loading clinical trials...
A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
Conditions
Interventions
Bempegaldesleukin
Nivolumab
Locations
70
United States
San Francisco VA Medical Center - NAVREF - PPDS
San Francisco, California, United States
Innovative Clinical Research Institute, LLC
Whittier, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Southeastern Regional Medical Center - CTCA - PPDS
Newnan, Georgia, United States
Investigator Site - Peoria
Peoria, Illinois, United States
Start Date
April 29, 2019
Primary Completion Date
February 9, 2022
Completion Date
June 30, 2022
Last Updated
March 28, 2023
NCT04389632
NCT07174336
NCT07495072
NCT07213804
NCT07046923
NCT07222488
Lead Sponsor
Nektar Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions